Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

PURPOSE: A phase II study was conducted to determine the response rate of ixabepilone (BMS-247550, National Cancer Institute (NCI)–supplied agent investigational new drug No. 59,699) in patients with persistent or recurrent endometrial cancer who have progressed despite standard therapy. PATIENTS AN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dizon, Don S., Blessing, John A., McMeekin, D. Scott, Sharma, Sudarshan K., DiSilvestro, Paul, Alvarez, Ronald D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2716935/
https://ncbi.nlm.nih.gov/pubmed/19451430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6995
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados